Evidence map›Paper›PMID 37802739›Full record

ArticleTrends in cancer2024

Updating cancer research with patient-focused networks.

Manuel Valiente, Eva Ortega-Paino

Abstract read
In one paragraph

Article in Trends in cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Current preclinical models of brain metastasis.Clinical & experimental metastasis · 2024
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Manuel ValienteBrain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; RENACER, Madrid, Spain. Electronic address: mvaliente@cnio.es.
Eva Ortega-PainoRENACER, Madrid, Spain; Biobank, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Electronic address: eortega@cnio.es.

Funding

AstraZeneca 10049582/5522European Regional Development Fund (ERDF-EU) (PID2021-124582OB-I00Fundación Ramón Areces CIVP20S10662 (E.O.P.) AND CIVP19S8163
6 · The paper itself

Abstract

Multidisciplinary patient-centered networks offer access to difficult-to-get samples and initiate projects from human material. Improving such networks to include 'living' samples could be transformative, not only for research but for clinical trial design, especially when focused on unmet clinical needs, such as brain metastasis.

Indexed as

Biomedical ResearchBrain NeoplasmsHumansbiobankdrug-screeningnetworkomicspatient-derived organotypic culture (PDOC)personalized medicine

Identifiers

PMID37802739
PMCPMC10777485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.